Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Erlotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 17/20 | 0.89 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.89 |
| ▸ | GAK | O14976 | 3/20 | 0.89 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.89 |
| ▸ | BUB1 | O43683 | 2/20 | 0.89 |
| ▸ | STK10 | O94804 | 2/20 | 0.89 |
| ▸ | ABL1 | P00519 | 2/20 | 0.89 |
| ▸ | LCK | P06239 | 2/20 | 0.89 |
| ▸ | LYN | P07948 | 2/20 | 0.89 |
| ▸ | RET | P07949 | 2/20 | 0.89 |
| ▸ | SRC | P12931 | 2/20 | 0.89 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.89 |
| ▸ | FECH | P22830 | 2/20 | 0.89 |
| ▸ | KDR | P35968 | 2/20 | 0.89 |
| ▸ | FLT3 | P36888 | 2/20 | 0.89 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.89 |
| ▸ | ILK | Q13418 | 2/20 | 0.89 |
| ▸ | PLK4 | O00444 | 1/20 | 0.89 |
| ▸ | CIT | O14578 | 1/20 | 0.89 |
| ▸ | AURKA | O14965 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erlotinib SCHEMBL20721119 | 0.96 | EGFR (0.89) | EGFRERBB2GAKRIPK2BUB1 | |
| Erlotinib SCHEMBL2034496 | 0.95 | EGFR (0.87) | EGFRERBB2GAKRIPK2BUB1 | |
| Erlotinib SCHEMBL2037601 | 0.94 | EGFR (0.85) | EGFRERBB2GAKRIPK2BUB1 | |
| Erlotinib SCHEMBL29120903 | 0.94 | EGFR (0.96) | EGFRERBB2GAKRIPK2BUB1 | |
| Erlotinib SCHEMBL8413 | 0.94 | EGFR (1.00) | EGFRERBB2GAKRIPK2BUB1 | |
| Erlotinib SCHEMBL30362833 | 0.94 | EGFR (1.00) | EGFRERBB2GAKRIPK2BUB1 | |
| Erlotinib SCHEMBL3667407 | 0.94 | EGFR (1.00) | EGFRERBB2GAKRIPK2BUB1 | |
| Erlotinib SCHEMBL29351329 | 0.94 | EGFR (1.00) | EGFRERBB2GAKRIPK2BUB1 | |
| Erlotinib SCHEMBL14861156 | 0.94 | EGFR (0.84) | EGFRERBB2GAKRIPK2BUB1 | |
| Erlotinib SCHEMBL27974989 | 0.94 | EGFR (0.84) | EGFRERBB2GAKRIPK2BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411373-B1 | PROCESS FOR THE PREPARATION OF ERLOTINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | RANBAXY LAB LTD (IN) | 2015-10-21 | — | — | EP | disclosed |
| EP-2139868-B1 | PROCESS FOR PREPARATION OF ERLOTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | CIPLA LTD (IN) | 2015-07-29 | — | — | EP | disclosed |
| US-20140194624-A1 | Process for Preparation of Erlotinib and its Pharmaceutically Acceptable Salts | CIPLA LIMITED (IN) | 2014-07-10 | — | — | US | disclosed |
| US-8642758-B2 | Process for preparation of erlotinib and its pharmaceutically acceptable salts | CIPLA LIMITED (IN) | 2014-02-04 | — | — | US | disclosed |
| US-8440823-B2 | Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof | RANBAXY LABORATORIES LIMITED (IN) | 2013-05-14 | — | — | US | disclosed |
| US-20120101272-A1 | PROCESS FOR THE PREPARATION OF ERLOTINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2012-04-26 | — | — | US | disclosed |
| EP-2411373-A1 | PROCESS FOR THE PREPARATION OF ERLOTINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Ranbaxy Laboratories Limited (IN) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109443-A1 | PROCESS FOR THE PREPARATION OF ERLOTINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-30 | — | — | WO | disclosed |
| US-20100094004-A1 | Process for Preparation of Erlotinib and its Pharmaceutically Acceptable Salts | CIPLA LIMITED (IN) | 2010-04-15 | — | — | US | disclosed |
| EP-2139868-A2 | PROCESS FOR PREPARATION OF ERLOTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | Cipla Limited (IN) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008122776-A2 | PROCESS FOR PREPARATION OF ERLOTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | CIPLA LIMITED (IN) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101272-A1 | PROCESS FOR THE PREPARATION OF ERLOTINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | KRAS, EGFR, CSNK1E | EGFR 2/4885ERBB2 26/4885GAK 3907/4885 |
| US-20140194624-A1 | Process for Preparation of Erlotinib and its Pharmaceutically Acceptable Salts | ABL1, EGFR, KRAS | EGFR 2/4885ERBB2 7/4885GAK 2303/4885 |
| US-20100094004-A1 | Process for Preparation of Erlotinib and its Pharmaceutically Acceptable Salts | ABL1, EGFR, KRAS | EGFR 2/4885ERBB2 7/4885GAK 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.